A clinical model for identifying prevalent osteoporosis in postmenopausal women with type 2 diabetes mellitus: development, internal validation, and evaluation of the incremental value of the atherogenic index of plasma

Postmenopausal women with type 2 diabetes mellitus (T2DM) are at increased risk of osteoporosis. The association between the atherogenic index of plasma (AIP) and osteoporosis in postmenopausal women with type 2 diabetes mellitus (T2DM) remains uncertain, as does whether AIP provides additional information beyond conventional clinical variables for identifying prevalent osteoporosis. We aimed to develop and internally validate a clinical model for identifying prevalent osteoporosis and to assess whether AIP improves discrimination beyond routinely available clinical variables. This retrospective study included 864 hospitalized postmenopausal women with T2DM from June 2022 to December 2024. Osteoporosis status was determined using the DXA-based bone status classification recorded in the study dataset. Cross-sectional associations between candidate variables and prevalent osteoporosis were evaluated using univariate and multivariable logistic regression, and a nomogram was developed. Model performance was assessed using ROC analysis, bootstrap calibration, the Hosmer–Lemeshow test, and decision curve analysis. The incremental value of AIP was examined using likelihood ratio and DeLong tests. Among 864 participants, 343 (39.7%) had osteoporosis. Age, BMI, diabetes duration, and serum uric acid were associated with prevalent osteoporosis after multivariable adjustment. Longer diabetes duration was inversely associated with prevalent osteoporosis (OR = 0.96, 95% CI 0.94–0.98; P < 0.001). AIP was not statistically significant after adjustment (OR = 0.60, 95% CI 0.34–1.06; P = 0.079). The base-model nomogram showed acceptable discrimination (AUC = 0.753) and calibration (Hosmer–Lemeshow χ² = 5.442, P = 0.709; mean absolute calibration error = 0.022). Adding AIP produced only a minimal increase in AUC to 0.754 and did not significantly improve model fit (likelihood ratio test P = 0.077) or discrimination (DeLong P = 0.532). The internally validated base model showed acceptable discrimination and calibration for identifying prevalent osteoporosis among hospitalized postmenopausal women with T2DM in the development sample. AIP did not provide meaningful additional discriminatory information beyond routinely available clinical variables. The model should be regarded as a preliminary tool for identifying prevalent osteoporosis in this specific population. External validation in independent and more diverse populations, together with prospective evaluation, is required before broader clinical application or implementation.

Authors

Institutions

Publication Details

Journal
BMC Women s Health
Published
2026-11-17
DOI
https://doi.org/10.1186/s12905-026-04999-7
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A clinical model for identifying prevalent osteoporosis in postmenopausal women with type 2 diabetes mellitus: development, internal validation, and evaluation of the incremental value of the atherogenic index of plasma

Bing Liu, Hao Qi, Jing-Bo He, Lu Tan et al.
6 links
BMC Women s Health
Bone health and osteoporosis research
article

A clinical model for identifying prevalent osteoporosis in postmenopausal women with type 2 diabetes mellitus: development, internal validation, and evaluation of the incremental value of the atherogenic index of plasma

Bing Liu, Hao Qi, Jing-Bo He, Lu Tan, Zhengsheng Duan, Pei Liu
article en

Abstract

Postmenopausal women with type 2 diabetes mellitus (T2DM) are at increased risk of osteoporosis. The association between the atherogenic index of plasma (AIP) and osteoporosis in postmenopausal women with type 2 diabetes mellitus (T2DM) remains uncertain, as does whether AIP provides additional information beyond conventional clinical variables for identifying prevalent osteoporosis. We aimed to develop and internally validate a clinical model for identifying prevalent osteoporosis and to assess whether AIP improves discrimination beyond routinely available clinical variables. This retrospective study included 864 hospitalized postmenopausal women with T2DM from June 2022 to December 2024. Osteoporosis status was determined using the DXA-based bone status classification recorded in the study dataset. Cross-sectional associations between candidate variables and prevalent osteoporosis were evaluated using univariate and multivariable logistic regression, and a nomogram was developed. Model performance was assessed using ROC analysis, bootstrap calibration, the Hosmer–Lemeshow test, and decision curve analysis. The incremental value of AIP was examined using likelihood ratio and DeLong tests. Among 864 participants, 343 (39.7%) had osteoporosis. Age, BMI, diabetes duration, and serum uric acid were associated with prevalent osteoporosis after multivariable adjustment. Longer diabetes duration was inversely associated with prevalent osteoporosis (OR = 0.96, 95% CI 0.94–0.98; P < 0.001). AIP was not statistically significant after adjustment (OR = 0.60, 95% CI 0.34–1.06; P = 0.079). The base-model nomogram showed acceptable discrimination (AUC = 0.753) and calibration (Hosmer–Lemeshow χ² = 5.442, P = 0.709; mean absolute calibration error = 0.022). Adding AIP produced only a minimal increase in AUC to 0.754 and did not significantly improve model fit (likelihood ratio test P = 0.077) or discrimination (DeLong P = 0.532). The internally validated base model showed acceptable discrimination and calibration for identifying prevalent osteoporosis among hospitalized postmenopausal women with T2DM in the development sample. AIP did not provide meaningful additional discriminatory information beyond routinely available clinical variables. The model should be regarded as a preliminary tool for identifying prevalent osteoporosis in this specific population. External validation in independent and more diverse populations, together with prospective evaluation, is required before broader clinical application or implementation.

BMC Women s Health
Shanxi Medical University (CN), Changzhi Medical College (CN), Shanxi Province Hospital of Traditional Chinese Medicine (CN), First Hospital of Shanxi Medical University (CN), Shanxi University of Traditional Chinese Medicine (CN), Shanxi Cardiovascular Hospital (CN)
Good health and well-being
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon